Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -243.79M | -293.70M | -274.18M | -254.02M | -235.93M |
| Total Depreciation and Amortization | 631.00K | 640.00K | 657.00K | 668.00K | 668.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.58M | 98.14M | 94.94M | 85.78M | 80.88M |
| Change in Net Operating Assets | 22.64M | 10.88M | -19.75M | -5.62M | -8.90M |
| Cash from Operations | -182.94M | -184.04M | -198.33M | -173.19M | -163.28M |
| Capital Expenditure | 0.00 | -819.00K | -856.00K | -856.00K | -117.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -70.56M | 42.74M | -90.40M | -87.58M | 64.50M |
| Cash from Investing | -70.56M | 41.92M | -91.25M | -88.43M | 64.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 21.60M | 6.59M | 239.72M | 237.47M | 236.23M |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -491.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -1.05M | -3.68M | -3.79M | -3.80M |
| Cash from Financing | 21.60M | 5.55M | 236.04M | 233.68M | 231.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -231.89M | -136.57M | -53.54M | -27.94M | 133.05M |
